Updated:
Merlin BioMed Group
Merlin BioMed Group was founded in 1999 by David Z. Schreiber, who structured the firm as a hybrid vehicle combining direct venture investments with merchant...
Merlin BioMed Group
Merlin BioMed Group was founded in 1999 by David Z. Schreiber, who structured the firm as a hybrid vehicle combining direct venture investments with merchant banking advisory work — an architecture designed to generate proprietary deal flow in the life sciences. The firm operates from Greenwich, Connecticut, and has historically functioned as a single-family-backing entity that also manages capital for a small number of aligned families, placing it at the intersection of a family office and a specialized asset manager. Its founding coincided with the genomics and biotech boom of the late 1990s, positioning it to build relationships across academic medical centers and early-stage therapeutic platforms. The firm deploys capital across private and public life science companies, with a mandate spanning pre-clinical biotech, medical device approvals, and revenue-stage digital health platforms. Its investment model emphasizes co-investment with established venture firms and pharmaceutical corporate venture arms rather than leading rounds — a posture that has historically given it access to syndicates alongside Orbimed Advisors and Novo Holdings. Known portfolio exposures have included Regeneron Pharmaceuticals during its early commercial ramp, and the firm has participated in multiple device and therapeutic exits via acquisition by larger strategics. Geographically, the group concentrates on North American and European innovation clusters, including the Boston-Cambridge corridor, San Diego, and the Zurich-London biotech axis. The firm operates as a lean organization with a deliberately small team, typical of family-backed venture platforms that avoid management-fee dependency. Merchant banking revenues from advisory mandates provide a differentiated non-AUM income stream, reducing pressure to deploy capital in unfavorable cycles. The group does not disclose a single unified AUM figure, and its public profile has remained intentionally low — no website by 2026, limited press, and no LinkedIn presence. This opacity is consistent with a firm that functions more as an extension of a principal's network than as a third-party capital gatherer. Merlin BioMed's structural distinction is its dual mandate as both a balance-sheet investor and a fee-generating advisor to life science companies — a model reminiscent of pre-Glass-Steagall merchant banking adapted to the biotech ecosystem. This architecture allows it to diligence companies through transactional advisory work before committing equity, effectively blending investment banking sourcing with venture portfolio construction. The model has survived the migration of most family offices toward either pure fund-of-funds or direct-only mandates, suggesting deliberate design rather than ad-hoc evolution.
General information
Firm type
Multi Family Office
Year founded
1999
AUM
$500M - $1B (Altss estimate)
Location
Region
North America
Country
United States
City
Greenwich
Corporate office
Greenwich, CT, United States
Principals
David Z. Schreiber
Chairman & CEO
Sector focus
Frequently asked questions
Who runs investment decisions at Merlin BioMed Group?
David Z. Schreiber, the founder and CEO, is the central decision-maker. The firm has historically operated with a small team, meaning investment approvals are not committee-driven in the way they would be at a large institutional fund. Schreiber's background spans both venture investing and transactional advisory work in the life sciences, which shapes the firm's dual deployment and advisory model.
How does Merlin BioMed source its deals?
The firm sources through a combination of its merchant banking advisory engagements and long-standing relationships across academic medical centers and venture syndicates. Because it advises life science companies on strategy and transactions, it gains visibility into opportunities before they go to broad auction. Its co-investment posture — joining syndicates rather than leading — also means it gets allocation invitations from top-tier healthcare venture firms.
Is Merlin BioMed Group a single family office or an asset manager accepting outside capital?
It operates as a hybrid. The firm was founded as the investment vehicle for a single principal and has historically managed capital for a small, private circle of aligned families. It does not market to institutional investors or operate as a registered investment advisor raising third-party funds on a broad basis. That said, its merchant banking arm generates advisory fees from non-portfolio companies, creating a revenue stream independent of the family capital base.
Does Merlin BioMed participate in fund commitments or only direct deals?
The firm's primary activity is direct co-investment in private life science companies, and occasionally public equity positions in the sector. There is no public record of Merlin BioMed acting as a significant limited partner in third-party venture funds. The preference appears to be for direct company exposure, often accessed through relationships with venture firms rather than through blind-pool fund commitments.
Which sectors does Merlin BioMed explicitly avoid?
The firm is exclusively focused on the life sciences, which means it does not invest in generalist technology, consumer, fintech, or industrial sectors. Within life sciences, there is no evidence of activity in healthcare services roll-ups or revenue-cycle management businesses — its portfolio emphasis has been on therapeutics, devices, and digital health platforms with intellectual property or regulatory moats.
What is Merlin BioMed's relationship to Regeneron Pharmaceuticals?
Merlin BioMed Group was an early investor in Regeneron Pharmaceuticals during the company's transition from a research-stage biotech to a commercial enterprise. David Z. Schreiber was involved during a formative period for Regeneron, and this relationship is often cited as a foundational case study for the firm's model of backing platform biotech companies with long development timelines.
Why does Merlin BioMed Group maintain such a low public profile?
The firm has never raised institutional third-party funds, so it has no marketing imperative. Its capital comes from a closed circle of families, and its deal flow is relationship-driven rather than sourced through inbound founder applications. Low visibility is a deliberate choice consistent with firms that treat their investment activities as extensions of a principal's personal network rather than as a brand to be built for asset-gathering purposes.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: